JP Morgan Chase
PMVP icon

JP Morgan Chase’s PMV Pharmaceuticals PMVP Stock Holding History

JP Morgan Chase’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276 Hold
214
– – ﹤0.01% 7476
2026
Q1 		$261 Hold
214
– – ﹤0.01% 7233
2025
Q4 		$268 Sell
214
-700
-77% -$938 ﹤0.01% 7132
2025
Q3 		$1.28K Hold
914
– – ﹤0.01% 6963
2025
Q2 		$969 Sell
914
-10,535
-92% -$10.3K ﹤0.01% 6626
2025
Q1 		$12.5K Sell
11,449
-13,142
-53% -$17.8K ﹤0.01% 6254
2024
Q4 		$37.1K Buy
24,591
+23,559
+2,283% +$37.3K ﹤0.01% 6109
2024
Q3 		$1.54K Sell
1,032
-199,513
-99% -$308K ﹤0.01% 6664
2024
Q2 		$325K Buy
200,545
+81,276
+68% +$147K ﹤0.01% 4907
2024
Q1 		$203K Sell
119,269
-3,811,071
-97% -$7.12M ﹤0.01% 5346
2023
Q4 		$12.2M Sell
3,930,340
-103,381
-3% -$274K ﹤0.01% 2273
2023
Q3 		$24.8M Sell
4,033,721
-41,783
-1% -$287K ﹤0.01% 1523
2023
Q2 		$25.5M Buy
4,075,504
+72,620
+2% +$381K ﹤0.01% 1526
2023
Q1 		$19.1M Sell
4,002,884
-93,667
-2% -$659K ﹤0.01% 1699
2022
Q4 		$35.6M Sell
4,096,551
-609,548
-13% -$6.5M ﹤0.01% 1286
2022
Q3 		$56M Sell
4,706,099
-213,224
-4% -$3.08M 0.01% 993
2022
Q2 		$70.1M Buy
4,919,323
+1,713,836
+53% +$24.9M 0.01% 895
2022
Q1 		$66.7M Buy
3,205,487
+38,265
+1% +$675K 0.01% 1021
2021
Q4 		$73.2M Buy
3,167,222
+1,360,130
+75% +$32.9M 0.01% 1022
2021
Q3 		$53.9M Buy
1,807,092
+164,028
+10% +$5.24M 0.01% 1142
2021
Q2 		$56.1M Buy
1,643,064
+707,674
+76% +$23.6M 0.01% 1164
2021
Q1 		$30.8M Buy
935,390
+898,291
+2,421% +$35.4M ﹤0.01% 1430
2020
Q4 		$2.28M Buy
37,099
+27,099
+271% +$1.06M ﹤0.01% 3385
2020
Q3 		$380K Buy
+10,000
New +$368K ﹤0.01% 4103

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

JP Morgan Chase's PMVP Position: Q2 2026 in Review

JP Morgan Chase held its PMV Pharmaceuticals (PMVP) position steady in Q2 2026 at 214 shares worth $276. The position accounts for ﹤0.01% of the portfolio, ranked #7476.

JP Morgan Chase first reported a position in PMVP in Q3 2020 and has held it in 24 quarters since. The position peaked at $73.2M in Q4 2021. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • JP Morgan Chase held 214 shares of PMV Pharmaceuticals worth $276 as of Q2 2026.
  • JP Morgan Chase left its PMV Pharmaceuticals share count unchanged in Q2 2026.
  • PMV Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7476 holding.
  • JP Morgan Chase first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's PMV Pharmaceuticals position peaked at $73.2M in Q4 2021.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.